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Background
Asthma is a complex and multi-factorial inflammatory
disease [1]. It is one of the most common chronic dis-
eases among children and adolescents [2]. Secretory leu-
kocyte protease inhibitor (SLPI) has shown higher levels
in asthmatic patients and its function as an anti-inflam-
matory protein has been documented in respiratory dis-
eases [3,4]. However, its role in the immunomodulation
of the response during allergic asthma has not yet been
fully elucidated. The aim of this study was to evaluate
the role of SLPI in the development of phenotypes asso-
ciated with allergic asthma, and the effect of resiquimod
treatment on the SLPI and the possible mechanisms of
action involved in the disease.
Materials and methods
The importance of SLPI was assessed by evaluating air-
way resistance and inflammatory parameters in SLPI
transgenic and knock-out mice using an ovalbumin
(OVA)-induced model of acute allergic asthma and
treatment with resiquimod.
Results
Allergic SLPI transgenic mice showed a significant
decrease in airway resistance compared to wild-type
mice (6.3 ± 1.1 vs. 8.0 ± 2.1 cm H20 × s/ml, p < 0.001),
the same effect was observed with inflammatory cell
infiltration, eosinophil percentage (24 ± 1.1% vs. 29 ±
2.3%, p < 0.001), goblet cells (6 ± 1.4 vs. 36 ± 4.0%, p <
0.001) in the lungs and IgE levels (2014.1 ± 309.2 vs.
4173.2 ± 685.6 ng/ml, p < 0.001) in plasma. Allergic
SLPI knock-out mice displayed significantly higher
values compared to wild-type mice. They include lung
resistance (8.6 ± 2.7 vs. 6.6 ± 0.5 cm H20*s/ml, p <
0.001), inflammatory cell influx, eosinophils (36.0 ± 2.7
vs. 29.0 ± 1.5%, p < 0.001), goblet cells (40 ± 4.1 vs. 30
± 1.4%, p < 0.001), cytokine levels in the lungs (p <
0.05) and plasma IgE levels (3598 ± 204.7 vs. 2763 ±
220.3 ng/ml, p < 0.001). Expression of SLPI decreased
inflammation in the lungs, plasma IgE levels, and lung
resistance, whereas the ablation of SLPI has the opposite
effect. Treatment with resiquimod improved airway
resistance and inflammation of the lungs in SLPI knock-
out and wild type, demonstrating that its effect is inde-
pendent of the expression of SLPI.
Conclusions
SLPI plays an immunoregulatory role in the respiratory
tract by reducing the inflammatory process and by
improving lung physiology in a murine model of acute
allergic asthma.
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